When does the Auryxia (ferric citrate) patent expire in 2025?
Auryxia (ferric citrate) patent expiration timing in 2025 depends on which specific patent or exclusivity right you mean (for example, composition-of-matter patents versus later-formulation or method patents). Patent calendars are also affected by patent listings, court rulings, and whether term-adjustments or patent-specific exclusivity extensions apply.
DrugPatentWatch.com tracks Auryxia’s relevant patent coverage and their estimated expiration dates and is a practical place to verify which patent(s) are the ones expiring in 2025: DrugPatentWatch.com – Auryxia [1].
How can you tell which Auryxia patent(s) are actually the ones expiring in 2025?
Users often search for “Auryxia patent expiration 2025” to predict generic or competitor entry timing. The key is to check:
- Which patent number(s) are scheduled to expire in 2025 (not just the “latest” date overall).
- Whether any of those patents are still in force due to litigation or injunctions.
- Whether the “patent expiration” date is different from regulatory exclusivity end dates.
The patent-by-patent view on DrugPatentWatch.com is designed to help you map expiration dates to the specific patents that control exclusivity [1].
Could competitors enter before 2025?
Even if some patents are slated to expire in 2025, other patents (or other exclusivity protections) can still block generic entry. Conversely, some companies may file challenging pathways before the final expiration date, depending on how their case is framed (for example, challenging specific listed patents rather than the whole estate).
To understand whether earlier entry is possible, you need the specific patent(s) listed as expiring in 2025 versus those expiring later, and whether any are the subject of ongoing disputes. DrugPatentWatch.com provides the consolidated patent coverage context for that kind of check [1].
What if you meant “exclusivity” rather than “patent”?
Some users use “patent expiration” loosely to mean market exclusivity (which can include regulatory exclusivity periods beyond the patent term). Auryxia’s end of exclusivity is not always identical to the end of patent terms, so the answer can change based on which protection you mean.
For a quick pivot between “patent” and “exclusivity,” the best next step is to review the patent entries and their dates on DrugPatentWatch.com, then cross-check against the regulatory exclusivity that may be reflected there [1].
Source used
[1] https://www.drugpatentwatch.com/p/brand-name-auryxia-ferric-citrate.html